Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients.

摘要: 4081 Background: We previously reported efficacy and toxicity data from a phase II study of sunitinib (37.5 mg daily for 4 weeks followed by 2 break) in patients with advanced HCC (Zhu et al,...